



ŧ



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/147,052		04/05/1999	SHUJI SAITOH	981167	1182	
23850	7590	07/16/2002				
ARMSTRONG,WESTERMAN & HATTORI, LLP				EXAMINER		
1725 K STR SUITE 1000		<b>7.</b>	HINES, JANA A			
WASHING		20006		21,050,211,1050		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,			ART UNIT	PAPER NUMBER	
				1645	02	
				DATE MAILED: 07/16/2002	27	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)					
Advisory Action	09/147,052	SAITOH ET AL.					
Advisory Action	Examiner	Art Unit					
	Ja-Na A Hines	1645					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	rrespondence add	ress				
THE REPLY FILED 18 March 2002 FAILS TO PLACE T Therefore, further action by the applicant is required to ave final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applicate)  a timely filed amendment which	ation. A proper repl n places the applica	y to a ition in				
PERIOD FOR RE	EPLY [check either a) or b)]						
a) The period for reply expiresmonths from the mailin b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offictimely filed, may reduce any earned patent term adjustment.	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing a FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CFI extension and the corresponding amount the shortened statutory period for reply cellater than three months after the mail	g date of the final rejecting FINAL REJECTION.  R 1.136(a) and the apprunt of the fee. The approriginally set in the final	on. See MPEP opriate extension ropriate extension Office action; or				
1. A Notice of Appeal was filed on 19 April 2002. App. 37 CFR 1.192(a), or any extension thereof (37 CFI	R 1.191(d)), to avoid dismissal o		ı in				
2. The proposed amendment(s) will not be entered be							
(a) X they raise new issues that would require further		see NOTE below);					
(b) they raise the issue of new matter (see Note be							
(c)  they are not deemed to place the application i issues for appeal; and/or							
(d) they present additional claims without cancel	(d) They present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following reject	ion(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed	amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NO	T place the				
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which wer	e newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	t(s) a)⊡ will not be entered or by ould be rejected is provided belo	)□ will be entered a ow or appended.	and an				
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed: None.		•					
Claim(s) objected to: <i>None</i> .							
Claim(s) rejected: <u>20-26</u> .							
Claim(s) withdrawn from consideration:							
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Exam	iner.				
9. Note the attached Information Disclosure Stateme							
10. Other:		_					
	f						
	M/ PRIN	ARK NAVARRO MARY EXAMINER					

U.S. Patent and Trademark Office PTO-303 (Rev. 04-01) Continuati n Sheet (PTO-303)

Applicati n No. 09/147,052

Continuation of 2. NOTE: The proposed an indiment raises issues of new matter and such amendments require further consideration annund search, therefore the amendment will not be entered. Newly amended claims 25-26 are now drawn to DNA comprising a first DNA sequence from M.gallisepticum and a second DNA sequence from a Marek's gene, however the claims do not define the DNA sequences. Therefore it appears that the claims fails to particularly describe the specific DNA sequences. Moreover, applicants have not pointed to by page and line number support for the newly claimed DNA sequences or support that an avipox virus comprising said DNA will be effective as a recombinant live vaccine. Therefore the claims appear incorporate new matter requiring further search and consideration, thus the amendment will not be entered.